Health Care & Life Sciences » Biotechnology | Protalix BioTherapeutics Inc.

Protalix BioTherapeutics Inc. | Mutual Funds

Mutual Funds that own Protalix BioTherapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
I.B.I. Yeter
592,275
0.41%
0
0.67%
06/28/2018
APO Medical Opportunities
346,500
0.24%
346,500
0.03%
03/31/2018
335,999
0.23%
2,622
0.8%
05/31/2018
Maor Luski Selected Shares
300,428
0.21%
109,886
3.16%
05/31/2018
282,771
0.19%
0
0.26%
09/06/2018
I.B.I. Menayot
276,803
0.19%
0
0.39%
06/28/2018
Bridgeway Ultra Small Company Market Fund
271,672
0.19%
0
0.03%
12/31/2017
247,166
0.17%
13,035
2.04%
06/28/2018
I.B.I. Foreign Equity Liable
218,032
0.15%
0
0.23%
06/28/2018
Top Alpha Overseas Shares
204,700
0.14%
0
0.75%
06/28/2018

About Protalix BioTherapeutics

View Profile
Address
2 Snunit Street
Carmiel HZ 21614
Israel
Employees -
Website http://www.protalix.com
Updated 07/08/2019
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.